Dal 2012 al 2014:

Subinvestigator per lo studio: ” A Prospective Observational Safety Study in Patients with Advanced Prostate Cancer Treated with firmagon (Degarelix) or a GnRH Agonist”.

2014:

Subinvestigator per lo studio: “An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)”.

2018 ad oggi:

Principal investigator Studio clinico dal titolo: “A randomized, Double-blind, Placebo-controlled, phase 3 study of Apalutamide in subjects with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy”.